![Foto de BELLINDA](/img/nophoto.png)
BELLINDA
BENHAMÚ SALAMA
Profesora titular de universidad
Publicacións (60) Publicacións de BELLINDA BENHAMÚ SALAMA
2024
-
Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota-Inspired Synthetic Compound Targeting NPM1 for Leukemia
JACS Au, Vol. 4, Núm. 5, pp. 1786-1800
2022
-
2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1Receptor for Parkinson's Disease
Journal of Medicinal Chemistry, Vol. 65, Núm. 18, pp. 12256-12272
-
Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "diabesity"
Journal of Medicinal Chemistry, Vol. 65, Núm. 7, pp. 5449-5461
-
New Trends in Aging Drug Discovery
Biomedicines, Vol. 10, Núm. 8
2019
-
Allosteric modulators targeting GPCRs
GPCRs: Structure, Function, and Drug Discovery (Elsevier), pp. 195-241
2017
-
A Positive Allosteric Modulator of the Serotonin 5-HT2C Receptor for Obesity
Journal of Medicinal Chemistry, Vol. 60, Núm. 23, pp. 9575-9584
-
A new serotonin 5-HT 6 receptor antagonist with procognitive activity - Importance of a halogen bond interaction to stabilize the binding
Scientific Reports, Vol. 7
-
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells
Oncotarget, Vol. 8, Núm. 7, pp. 11600-11613
2016
-
Chemoproteomic approach to explore the target profile of GPCR ligands: Application to 5-HT1A and 5-HT6 receptors
Chemistry - A European Journal, Vol. 22, Núm. 4, pp. 1313-1321
2015
-
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells
International Journal of Cancer, Vol. 136, Núm. 9, pp. 2078-2090
2014
-
Serotonin 5-HT6receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease
Journal of Medicinal Chemistry, Vol. 57, Núm. 17, pp. 7160-7181
-
The extracellular entrance provides selectivity to serotonin 5-HT 7 receptor antagonists with antidepressant-like behavior in vivo
Journal of Medicinal Chemistry, Vol. 57, Núm. 15, pp. 6879-6884
2013
-
New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo
Journal of Medicinal Chemistry, Vol. 56, Núm. 20, pp. 7851-7861
2012
-
New synthetic inhibitors of fatty acid synthase with anticancer activity
Journal of Medicinal Chemistry, Vol. 55, Núm. 11, pp. 5013-5023
2011
-
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Breast Cancer Research, Vol. 13, Núm. 6
-
Development of non-peptide ligands of growth factor receptor-bound protein 2-src homology 2 domain using molecular modeling and NMR spectroscopy
Journal of Medicinal Chemistry, Vol. 54, Núm. 4, pp. 1096-1100
-
New serotonin 5-HT 1A receptor agonists with neuroprotective effect against ischemic cell damage
Journal of Medicinal Chemistry, Vol. 54, Núm. 23, pp. 7986-7999
-
The importance of solvation in the design of ligands targeting membrane proteins
MedChemComm, Vol. 2, Núm. 3, pp. 160-164
2010
-
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation
Journal of Medicinal Chemistry, Vol. 53, Núm. 3, pp. 1357-1369
-
Development of fluorescent ligands for the human 5-HT1A receptor
ACS Medicinal Chemistry Letters, Vol. 1, Núm. 6, pp. 249-253